Pretreatment by omalizumab allows allergen-specific immunotherapy in children and young adult with severe allergic asthma
نویسندگان
چکیده
Background Subcutaneous allergen-specific immunotherapy (SCIT) is a valuable treatment option for patients with controlled mild to moderate allergic asthma However, SCIT is contraindicated for patients with severe persistent asthma due to a potential systemic allergic reaction. Several studies in adolescents and adults with persistent allergic rhinitis and moderate persistent allergic asthma have shown that SCIT is better tolerated when combined with. Nevertheless, no previous studies have been conducted in children and adolescents with severe asthma to assess the safety and efficacy of a combination treatment of SCIT and omalizumab.
منابع مشابه
Recent Progress in Allergen Immunotherapy
The efficacy of allergen immunotherapy for the treatment of allergic rhinoconjunctivitis with or without seasonal bronchial asthma and anaphylaxis caused by the sting of the hymenoptera class of insects has been clearly demonstrated in numerous well-designed, placebo-controlled trials. Immunotherapy whether by subcutaneous injection of allergen extract or by oral/sublingual routes modifies peri...
متن کاملChildren with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland
Anti-IgE treatment reduces exacerbations, symptoms and, in some patients, the dose of inhaled glucocorticoids needed to maintain asthma control [1–3]. Omalizumab, a monoclonal anti-immunoglobulin E anti-body, has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with severe persistent allergic asthma who experience frequent symptoms and have ...
متن کاملTreatment of life-threatening food allergy
Background Food allergy may be life-threatening and affected individuals have impairment in quality of life. Children with multiple and severe food allergies usually have other allergic manifestations like allergy to furry animals and pollen, causing eczema and asthma. Treatment with the anti-IgE (omalizumab) is indicated for severe allergic asthma. Oral immunotherapy (OIT) has been performed i...
متن کاملOmalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
BACKGROUND Rush immunotherapy (RIT) presents an attractive alternative to standard immunotherapy. However, RIT carries a much greater risk of acute allergic reactions, including anaphylaxis. OBJECTIVES We hypothesized that omalizumab, a humanized monoclonal anti-IgE antibody, would be effective in enhancing both safety and efficacy of RIT. METHODS Adult patients with ragweed allergic rhinit...
متن کاملSeasonal omalizumab reduces allergen-specific immunoglobulin E levels in patients with Japanese cedar pollinosis and asthma.
In Japan, Japanese cedar pollinosis (JCP) is one of the most prevalent forms of seasonal allergic rhinitis (AR). The JC pollen scattering period starts at the beginning of February and finishes at the end of April. JCP and asthma present concurrently; a previous survey showed that the prevalence of JCP in patients with asthma might be up to 30%--50%. Moreover, JCP is often associated with exace...
متن کامل